LATEST

Secukinumab safe and effective through 5 years in psoriasisPatients were continually treated with the 300 mg for five years.
Recapture remission in chronic idiopathic urticariaIn CIU, omalizumab retreatment recaptures remission in relapsers following drug withdrawal.
Oral baricitinib instead of topicals for atopic dermatitis?EADV study shows that this JAK inhibitor is a promising drug candidate in moderate-to-severe AD.
Update: Immunotherapeutic options in advanced melanomaAt EADV, Dr. Simone Ribero reviews the latest data on new treatments for advanced melanoma.
Avelumab safety profile is “acceptable”Immunotherapy improves Merkel cell carcinoma, but questions remain.
Look beyond diagnosis to see beauty and humanity
Look beyond diagnosis to see beauty and humanityAs the 26th European Academy of Dermatology and Venereology Congress opens this week in Geneva, meeting attendees were treated to a talk by medical photographer Rick Guidotti.
Do we need pigment to develop melanoma?
Do we need pigment to develop melanoma?New insights into the pigment pathway are improving the understanding of how immunotherapy works in melanoma.
Guselkumab front and center at EADV Congress
Guselkumab front and center at EADV CongressIL-23 inhibitors represent one more very effective strategy for controlling psoriasis with PASI rates comparable to other biologics.
Botanical ingredients reduce mild acne-related erythema
Botanical ingredients reduce mild acne-related erythemaA combination of salicylic acid and botanicals commonly may provide anti-inflammatory benefits as a spot treatment for acne.
Azelaic acid reduces truncal acne
Azelaic acid reduces truncal acneA new azelaic acid 15% foam may provide a viable alternative to oral treatments for truncal acne.

Poll

View Results